The orphan drug act restoring the mission to rare diseases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 39, Issue 2, 2016, Pages 210-213

  Daniel, Michael G ^a   Pawlik, Timothy M ^a   Fader, Amanda N ^a   Esnaola, Nestor F ^b   Makary, Martin A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Health policy; Orphan Drug Act; Orphan drugs; Rare diseases

Indexed keywords

ORPHAN DRUG;

ACT; ARTICLE; DILUTION; DRUG COST; FOOD AND DRUG ADMINISTRATION; HUMAN; LAW; OFF LABEL DRUG USE; ORPHAN DRUG ACT; RARE DISEASE; DRUG APPROVAL; DRUG MANUFACTURE; LEGISLATION AND JURISPRUDENCE; RARE DISEASES; UNITED STATES;

DRUG APPROVAL; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES; UNITED STATES;

EID: 84947465864     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000251     Document Type: Article

References (19)

1. Boat TF, Adamson PC, Asbury C, et al. Rare Diseases and Orphan Products, Accelerating Research and Development Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development. Washington DC: National Academies Press; 2010.
2. Office of Orphan Products Development. US food and drug administration. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/Officeof ScienceandHealthCoordination/ucm2018190.htm. Accessed February 18, 2015.
3. US Food and Drug Administration. FAQ Concerning the Orphan Products Grants Program, Office of Orphan Products Development. Available at: http://www.fda.gov/ForIndustry/Developing ProductsforRareDiseasesConditions/WhomtoContactaboutOrphan ProductDevelopment/ucm224956.htm. Accessed April 24, 2015.
4. Kaitlin KI, Richard BW, Lasagna L. Trends in drug development: the 1985-1986 new drug approvals. J Clin Pharmacol. 1987;27: 542-548.
5. Kaitlin KI, Manocchia M. The new drug approvals of 1993, 1994, and 1995: trends in drug development. Am J Ther. 1997;4:46-54.
6. New Drug Approvals in 2011. Presented by America's Biophar-maceutical Research Companies, 2012 Report.
7. Novel New Drugs 2014 Summary, US Food and Drug Administration: Center for Drug Evaluation and Research, January 2015.
8. NME Drug and New Biologic Approvals in 2005, US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/De velopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm081676.htm. Accessed February 26, 2015.
9. Hadjivasiliou A, Gardner J. Orphan Drug Report 2014. Evalua-tePharma. 2014.
10. Urquhart L, Brown A, Gardner J, et al. Pharma & Biotech 2015 Preview. EvaluatePharma. 2014.
11. Hornberger J, Chien R, Friedmann M, et al. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkins lymphoma after responding to first-line rituximab plus chemotherapy. Informa Healthcare. 2012;53:2371-2377.
12. Faloon W. Unsustainable, cancer drug prices. Life Extension Magazine. 2014 April. Available at: http://www.lef.org/magazine/2014/4/Unsus-tainable-Cancer-Drug-Prices/Page-01. Accessed May 7, 2015.
13. Cortes J, Calvo E, Vivancos A, et al. New approach to cancer therapy based on a molecularly defined cancer classification. Cancer J Clin. 2014;64:70-74.
14. American College of Rheumatology. Prevalence Statistics. Available at: http://www.rheumatology.org/Research/Prevalence- Statistics/. Accessed April 19, 2015. Accessed April 19, 2015.
15. The Economic Power of Orphan Drugs, Thomson Reuters, 2012, Food and Drug Administration, HHS. Food and Drug Administration Orphan Drug Regulations, Federal Register Vol. 78, No. 113, June 12, 2013.
16. Orphan Drug Designations and Approvals List as of September 2, 2014: Governs October 1, 2014-December 31, 2014.
17. Kesselheim AS, Myers JA, Solomon DH, et al. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS ONE. 2012;7:2.
18. Bush Pocket-Vetoes Orphan Drug Measure. In CQ Almanac 1990, 46th ed., 577-579. Washington, DC: Congressional Quarterly, 1991. Available at: http://library.cqpress.com/cqalmanac/cqal90-1113412. Accessed February 4, 2015.
19. Murphy SM, Puwanant A, Griggs RC, et al. Neurology argument against orphan drugs. Ann Neurol. 2012;72:481-490.